WO2003022875A3 - Polymorphisms of pd-1 - Google Patents

Polymorphisms of pd-1 Download PDF

Info

Publication number
WO2003022875A3
WO2003022875A3 PCT/EP2002/010011 EP0210011W WO03022875A3 WO 2003022875 A3 WO2003022875 A3 WO 2003022875A3 EP 0210011 W EP0210011 W EP 0210011W WO 03022875 A3 WO03022875 A3 WO 03022875A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
methods
identification
nucleic acids
provides nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/010011
Other languages
French (fr)
Other versions
WO2003022875A2 (en
Inventor
Marta Eugenia Alarcon-Riquelme
Ludmila Prokunina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EVERYGENE AB
Original Assignee
EVERYGENE AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121674A external-priority patent/GB0121674D0/en
Priority claimed from US10/219,446 external-priority patent/US20040033497A1/en
Application filed by EVERYGENE AB filed Critical EVERYGENE AB
Priority to EP02797957A priority Critical patent/EP1425421A2/en
Priority to AU2002362273A priority patent/AU2002362273A1/en
Publication of WO2003022875A2 publication Critical patent/WO2003022875A2/en
Publication of WO2003022875A3 publication Critical patent/WO2003022875A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is based at least in part on the identification of the genomic structure of the human PD-1 gene and on the identification of polymorphic region within the gene. Accordingly, the invention provides nucleic acids having a nucleotide sequence encoding variants of the PD-1 gene and also provides nucleic acids having a PD-1 promoter, intron, exon and 3' UTR sequences, and expression products. The invention also provides methods for identifying specific alleles of polymorphic regions of a PD-1 gene, methods for determining whether a subject has or at risk of developing any disease that is associated with a specific allele of a polymorphic region of a PD-1 gene, and kits for performing such methods.
PCT/EP2002/010011 2001-09-07 2002-09-06 Polymorphisms of pd-1 Ceased WO2003022875A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02797957A EP1425421A2 (en) 2001-09-07 2002-09-06 Polymorphisms of pd-1
AU2002362273A AU2002362273A1 (en) 2001-09-07 2002-09-06 Polymorphisms of pd-1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0121674A GB0121674D0 (en) 2001-09-07 2001-09-07 Nucleic acids encoding PD-1, polymorphs and uses thereof
GB0121674.6 2001-09-07
US10/219,446 2002-08-13
US10/219,446 US20040033497A1 (en) 2002-08-13 2002-08-13 Polymorphisms of PD-1

Publications (2)

Publication Number Publication Date
WO2003022875A2 WO2003022875A2 (en) 2003-03-20
WO2003022875A3 true WO2003022875A3 (en) 2003-10-16

Family

ID=26246520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010011 Ceased WO2003022875A2 (en) 2001-09-07 2002-09-06 Polymorphisms of pd-1

Country Status (3)

Country Link
EP (1) EP1425421A2 (en)
AU (1) AU2002362273A1 (en)
WO (1) WO2003022875A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089080A2 (en) * 2004-03-22 2005-09-29 Everygene Ab Method and kit for screening, pharmaceutical compositions and method for treatment of autoimmune disorders
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
JP5763341B2 (en) 2007-09-27 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Rapid in vivo identification of biologically active nucleases
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
BR112017018770A2 (en) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. reduced immune tolerance induced by pd-l1
WO2018084706A1 (en) * 2016-11-04 2018-05-11 Erasmus University Medical Center Rotterdam Markers for identifying patient classes and use thereof
WO2020068500A1 (en) * 2018-09-26 2020-04-02 Albert Einstein College Of Medicine Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE SWALLPROT [online] 1 November 1997 (1997-11-01), XP002243478, retrieved from EBI Database accession no. q15116 *
FINGER L R ET AL: "The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 197, no. 1-2, 15 September 1997 (1997-09-15), pages 177 - 187, XP004126417, ISSN: 0378-1119 *
PROKUNINA LUDMILA ET AL: "A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.", NATURE GENETICS, vol. 32, no. 4, 20 December 2002 (2002-12-20), pages 666 - 669, XP002243477, ISSN: 1061-4036 *
SHINOHARA T ET AL: "SHORT COMMUNICATION STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE HUMAN PD-1 GENE (PDCD1)", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 23, no. 3, 1 October 1994 (1994-10-01), pages 704 - 706, XP000647607, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
EP1425421A2 (en) 2004-06-09
AU2002362273A1 (en) 2003-03-24
WO2003022875A2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
WO2003089897A3 (en) Diagnosis and treatment of vascular disease
Sadler et al. A database of polymorphisms in the von Willebrand factor gene and pseudogene
WO2003016494A3 (en) Diagnosis and treatment of vascular disease
O'Neill et al. A gene for autosomal dominant late-onset progressive non-syndromic hearing loss, DFNA10, maps to chromosome 6
WO1999032644A3 (en) Prostate cancer gene
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
Skalníková et al. Cost-effective genotyping of human MBL2 gene mutations using multiplex PCR
WO2003087763A3 (en) Association of polymorphisms in the sost gene region with bone mineral density
WO2002062825A3 (en) Detection of polymorphisms in the human 5-lipoxygenase gene
Winship et al. An MseI RFLP in the 5’flanking region of the factor IX gene: its use for haemophilia B carrier detection in Caucasian and Thai populations
AU4766000A (en) Method for analysing a patient's genetic predisposition to at least a disease and amplification adapted to such a method
WO2003026488A3 (en) Diagnosis and treatment of vascular disease
Orrù et al. Psoriasis is associated with a SNP haplotype of the corneodesmosin gene (CDSN)
EP1255858A2 (en) Improved mutation analysis of the nf1 gene
US8071299B2 (en) Methods for predicting the response of multiple sclerosis patients to interferon therapy and diagnosing multiple sclerosis
WO2003020120A3 (en) Diagnosis and treatment of vascular disease
WO2002081644A3 (en) Haplotyping method for multiple distal nucleotide polymorphisms
Bonk et al. Molecular diagnosis of familial adenomatous polyposis (FAP): genotyping of adenomatous polyposis coli (APC) alleles by MALDI-TOF mass spectrometry
WO1999002735A3 (en) Diagnostic assays and kits for body mass and cardiovascular disorders
Miterski et al. PCR/SSCP detects reliably and efficiently DNA sequence variations in large scale screening projects
Góth Genetic heterogeneity of the 5′ uncoding region of the catalase gene in Hungarian acatalasemic and hypocatalasemic subjects
WO1999002736A3 (en) Sr-bi nucleic acids and uses therefor
WO2003007801A3 (en) Diagnosis and treatment of vascular disease
WO2003023063A1 (en) Method of judging onset risk of diabetes
WO2003020980A3 (en) Single nucleotide polymorphisms diagnostic for schizophrenia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002797957

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002797957

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002797957

Country of ref document: EP